The report notes a 1.5% YoY revenue decline and 24% YoY EBITDA decline in Q2FY27 due to lower lenalidomide sales, but states the company remains confident of medium-term growth from semaglutide relaunch, biosimilars and CDMO expansion, maintaining a Buy rating with FY27/FY28 estimates revised down for FY27 and mixed for FY28.
Read this note →Dr. Reddy's Laboratories Limited
NSE DRREDDY BSE 500124 INE089A01031
0 filings · 0 analysed
1,385.00
+0.41%
over today
-
The report notes a 1.5% YoY revenue decline and 24% YoY EBITDA decline in Q2FY27 due to lower lenalidomide sales, but states the company remains confident of medium-term growth from semaglutide relaunch, biosimilars and CDMO expansion, maintaining a Buy rating with FY27/FY28 estimates revised down for FY27 and mixed for FY28.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Sharekhan (Mirae Asset Sharekhan) | 19 Oct 2026, 18:09 | long | 1,242.50 | 1,295.00 | 1,310.90 | 130% | hit |
| Sharekhan Limited (Mirae Asset Sharekhan) | 07 Oct 2026, 16:25 | short | 1,203.80 | 1.00 | 1,373.00 | -14% | open by 2027-10-07 |
| HDFC Securities | 07 Oct 2026, 15:25 | short | 1,203.80 | 1,200.00 | 1,229.50 | -100% | hit |
| Religare Broking Ltd (religareonline.com) | 05 Oct 2026, 21:39 | short | 1,203.00 | 28.00 | 1,229.50 | -2% | missed |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report lists Dr Reddy's Laboratories among the top losers, down 0.66-2.03%.
Read this note →The report states the US FDA approved Dr. Reddy's India-made generic lenacapavir, a twice-yearly HIV prevention injection.
Read this note →The report lists Dr. Reddy's Laboratories among the top gainers, up 2.57-6.62%.
Read this note →The report notes DRL's consolidated net profit fell 36% YoY to ₹925 crore and revenue fell 1.5% to ₹8,670.8 crore in Q2 FY27.
Read this note →The report states overall quarterly performance was weak, with revenue declining 1.5% YoY and net profit down 31.3% YoY, below expectations.
Read this note →The report says Dr Reddy's EBITDA declined 27% YoY on a 3% sales decline driven by a 30% YoY US decline, with TP revised to INR 1,270 and REDUCE rating retained.
Read this note →The report lists Dr Reddy's under short covering with price up 0.09% and OI down 2.47%.
Read this note →The note gives a technical BUY call on Dr Reddy's at CMP 1243 with stoploss 1206 and targets of 1295 and 1330.
Read this note →The report lists Dr. Reddy's Laboratories among the top gainers, up 1.31-2.71%.
Read this note →The note records a sell call from October 7 where the first target was achieved and profit booked at 2.47%.
Read this note →Under Momentum Swing, the note shows a Sell call dated 07 Oct 26 at 1207 with a stop loss of 1223 and current price 1200.90.
Read this note →The report expects a 4% YoY revenue decline and a sharp EBITDA margin contraction due to absence of gRevlimid and price erosion, flagging it as a muted performer.
Read this note →The options-on-radar table lists a 1200 PE buy at 30-31 with SL 27 and target 37 on short buildup.
Read this note →The report lists a 1200 PE option buy on Dr Reddy's in the buying range 30-31 with SL 27 and target 37, citing Short Buildup.
Read this note →The note says Dr Reddy's has recovered from the 1,200 support zone, reclaimed its 20- and 50-DEMA with RSI above 50 and a positive MACD crossover, and proposes a bull call spread with hurdles at 1,250-1,260.
Read this note →The report states DRRD's US sales are expected to decline 35% YoY to USD236m due to g-Revlimid competition, driving a 43.8% YoY EBITDA decline and underwent two USFDA inspections with Form 483 observations.
Read this note →The note mentions Dr. Reddy's gained after the US exempted India from tariffs on certain pharma products, and lists it among stocks with a positive derivative setup.
Read this note →The derivative outlook section states a positive setup is seen in Dr Reddy.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief